EUVIMEDEUVIMED entdecken
Open Access

Treatment response as surrogate to predict risk for disease progression in pediatric medulloblastoma with persistent magnetic resonance imaging lesions after first-line treatment

Denise Obrecht-Sturm iD, Lena Schömig, Martin Mynarek iD, Brigitte Bison, Rudolf Schwarz, Torsten Pietsch, Stefan M Pfister iD, Martin Sill, Dominik Sturm, Felix Sahm iD, Rolf-Dieter Kortmann, Nicolas U Gerber und 6 weitere

Neuro-Oncology · 2024

DOI: 10.1093/neuonc/noae071 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2024. Verfasst von Denise Obrecht-Sturm und 17 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Hauptthemen laut MEDLINE: Medulloblastoma, Magnetic Resonance Imaging, Cerebellar Neoplasms, Disease Progression. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: German Children's Cancer Foundation, Deutsche Kinderkrebsstiftung, Steirische Kinderkrebshilfe.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study aims at clarifying the impact of persistent residual lesions following first-line treatment for pediatric medulloblastoma.

Methods

Data on 84 pediatric patients with medulloblastoma and persistent residual lesions on centrally reviewed magnetic resonance imaging (MRI) at the end of first-line therapy were analyzed.

Results

Twenty patients (23.8%) had residual lesions in the tumor bed (R+/M0), 51 (60.7%) had distant lesions (R0/M+) and 13 (15.5%) had both (R+/M+). Overall response to first-line therapy was minor or partial (≥ 25% reduction, minor response [MR]/PR) for 64 (76.2%) and stable disease (SD) for 20 patients (23.8%). Five-year post-primary-treatment progression-free (pptPFS) and overall survival (pptOS) were superior after MR/PR (pptPFS: 62.5 ± 7.0%[MR/PR] vs. 35.9 ± 12.8%[SD], P = .03; pptOS: 79.7 ± 5.9[MR/PR] vs. 55.5 ± 13.9[SD], P = .04). Furthermore, R+/M + was associated with a higher risk for progression (5-year pptPFS: 22.9 ± 17.9%[R+, M+] vs. 72.4 ± 12.0%[R+, M0]; P = .03). Watch-and-wait was pursued in 58 patients, while n = 26 received additional treatments (chemotherapy only, n = 19; surgery only, n = 2; combined, n = 3; valproic acid, n = 2), and their outcomes were not superior to watch-and-wait (5-year pptPFS: 58.5 ± 7.7% vs. 51.6 ± 10.7% P = .71; 5-year pptOS: 76.3 ± 6.9% vs. 69.8 ± 9.7%, P = .74). For the whole cohort, 5-year pptPFS by molecular subgroup (58 cases) were WNT: 100%, SHH: 50.0 ± 35.4%, group-4, 52.5 ± 10.5, group-3 54.2 ± 13.8%; (P = .08).

Conclusions

Overall response and extent of lesions can function as surrogate parameters to predict outcomes in pediatric MB patients with persistent lesions after first-line therapy. Especially in the case of solitary persistent medulloblastoma MRI lesions, additional therapy was not beneficial. Therefore, treatment response, extent/kind of residual lesions and further diagnostic information need consideration for indication of additional treatments for persisting lesions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MedulloblastomaMagnetic Resonance ImagingCerebellar NeoplasmsDisease ProgressionHumansMaleChildFemaleChild, PreschoolAdolescentFollow-Up StudiesPrognosisRetrospective StudiesSurvival RateInfantNeoplasm, Residual

Stichwörter der Autor:innen

MRIchildrenmedulloblastomapersistent residual disease

Autor:innen und Institutionen

  • Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Mildred Scheel Cancer Career Center HaTriCS4, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Department of Neuroradiology, University Hospital Augsburg, Augsburg, Germany.
  • Department for Radiotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Institute of Neuropathology, Brain Tumor Reference Center of the German Society for Neuropathology and Neuroanatomy (DGNN), University of Bonn, DZNE German Center for Neurodegenerative Diseases, Bonn, Germany.
  • Department of Pediatric Hematology and Oncology, Heidelberg University Hospital, Heidelberg, Germany.

ORCID-Profile: Denise Obrecht-Sturm, Martin Mynarek, Stefan M Pfister, Felix Sahm, Ulrich Schüller

Förderung

  • German Children's Cancer Foundation
  • Deutsche Kinderkrebsstiftung
  • Steirische Kinderkrebshilfe
  • German Children’s Cancer Foundation

Zitieren

APA

Obrecht-Sturm, D., Schömig, L., Mynarek, M., Bison, B., Schwarz, R., Pietsch, T., Pfister, S. M., Sill, M., Sturm, D., Sahm, F., Kortmann, R. D., Gerber, N. U., von Bueren, A. O., Fleischhack, G., Schüller, U., Nussbaumer, G., Benesch, M., & Rutkowski, S. (2024). Treatment response as surrogate to predict risk for disease progression in pediatric medulloblastoma with persistent magnetic resonance imaging lesions after first-line treatment. Neuro-Oncology. https://doi.org/10.1093/neuonc/noae071

Vancouver

Obrecht-Sturm D, Schömig L, Mynarek M, Bison B, Schwarz R, Pietsch T, et al. Treatment response as surrogate to predict risk for disease progression in pediatric medulloblastoma with persistent magnetic resonance imaging lesions after first-line treatment. Neuro-Oncology. 2024. doi:10.1093/neuonc/noae071

BibTeX
@article{ObrechtSturm2024,
  author = {Obrecht-Sturm, Denise and Schömig, Lena and Mynarek, Martin and Bison, Brigitte and Schwarz, Rudolf and Pietsch, Torsten and Pfister, Stefan M and Sill, Martin and Sturm, Dominik and Sahm, Felix and Kortmann, Rolf-Dieter and Gerber, Nicolas U and von Bueren, André O and Fleischhack, Gudrun and Schüller, Ulrich and Nussbaumer, Gunther and Benesch, Martin and Rutkowski, Stefan},
  title = {Treatment response as surrogate to predict risk for disease progression in pediatric medulloblastoma with persistent magnetic resonance imaging lesions after first-line treatment},
  journal = {Neuro-Oncology},
  year = {2024},
  doi = {10.1093/neuonc/noae071}
}
Kostenlos starten →